Firibastat in Treatment-resistant Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

515

Participants

Timeline

Start Date

June 25, 2020

Primary Completion Date

August 30, 2022

Study Completion Date

September 20, 2022

Conditions
Hypertension
Interventions
DRUG

Firibastat

Oral administration 2×250 mg capsules bid

DRUG

Placebo

Oral administration 2 capsules bid

Trial Locations (20)

10455

ClinEdge - Chear Center, The Bronx

15006

Fakultní nemocnice v Motole, Prague

20110

Manassas Clinical Research Center, Manassas

24105

Universitätsklinikum Schleswig-Holstein - Campus Kiel, Kiel

32127

Progressive Medical Research, Port Orange

32216

Jacksonville Center for Clinical Research, Jacksonville

34239

Cardiovascular Center of Sarasota, Sarasota

45219

Sterling Research Group - Cincinnati / Mount Auburn, Cincinnati

60607

Apex Medical Research, Chicago

Cedar Crosse Research Center, Chicago

67091

Les Hôpitaux Universitaires de Strasbourg, Strasbourg

75006

Insearch - Punzi Medical Center, Carrollton

77040

Juno Research - Corporate Office, Houston

77450

Insearch - R&H Clinical Research, Katy

82300

Ambulatorium Barbara Bazela, Elblag

92647

Marvel Clinical Research, Huntington Beach

92780

Orange County Research Center, Tustin

280006

Hospital Universitario de La Princesa, Madrid

35209-8401

Central Alabama Research, Birmingham

45406-5144

ClinEdge - Dayton Clinical Research, Dayton

All Listed Sponsors
lead

Quantum Genomics SA

INDUSTRY

NCT04277884 - Firibastat in Treatment-resistant Hypertension | Biotech Hunter | Biotech Hunter